G
Guang Chen
Researcher at Celgene
Publications - 22
Citations - 1126
Guang Chen is an academic researcher from Celgene. The author has contributed to research in topics: Lenalidomide & Multiple myeloma. The author has an hindex of 9, co-authored 21 publications receiving 964 citations.
Papers
More filters
Journal ArticleDOI
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma
Lotfi Benboubker,Meletios A. Dimopoulos,Angela Dispenzieri,John Catalano,Andrew Belch,Michele Cavo,Antonello Pinto,Katja Weisel,Heinz Ludwig,Nizar J. Bahlis,Anne Banos,Mourad Tiab,Michel Delforge,Jamie Cavenagh,Catarina Geraldes,Je-Jung Lee,Christine Chen,Albert Oriol,Javier de la Rubia,Lugui Qiu,Darrell White,Daniel Binder,Kenneth C. Anderson,Jean Paul Fermand,Philippe Moreau,Michel Attal,Robert Knight,Guang Chen,Jason Van Oostendorp,Christian Jacques,Annette Ervin-Haynes,Hervé Avet-Loiseau,Cyrille Hulin,Thierry Facon +33 more
TL;DR: Continuous lenalidomide-dexamethasone given until disease progression was associated with a significant improvement in progression-free survival, with an overall survival benefit at the interim analysis, among patients with newly diagnosed multiple myeloma who were ineligible for stem-cell transplantation.
Journal ArticleDOI
Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma
Thierry Facon,Meletios A. Dimopoulos,Angela Dispenzieri,John Catalano,Andrew Belch,Michele Cavo,Antonello Pinto,Katja Weisel,Heinz Ludwig,Nizar J. Bahlis,Anne Banos,Mourad Tiab,Michel Delforge,Jamie D. Cavenagh,Catarina Geraldes,Je-Jung Lee,Christine Chen,Albert Oriol,Javier de la Rubia,Darrell White,Daniel Binder,Jin Lu,Kenneth C. Anderson,Philippe Moreau,Michel Attal,Aurore Perrot,Bertrand Arnulf,Lugui Qiu,Murielle Roussel,Eileen M Boyle,Salomon Manier,Mohamad Mohty,Hervé Avet-Loiseau,Xavier Leleu,Annette Ervin-Haynes,Guang Chen,Vanessa Houck,Lotfi Benboubker,Cyrille Hulin +38 more
TL;DR: Treatment with Rd continuous significantly improved survival outcomes vs MPT, supporting Rd continuous as a standard of care for patients with transplant-ineligible multiple myeloma.
Journal ArticleDOI
Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial
Cyrille Hulin,Andrew R. Belch,Chaim Shustik,Maria Teresa Petrucci,Ulrich Dührsen,Jin Lu,Kevin W. Song,Philippe Rodon,Brigitte Pegourie,Laurent Garderet,Hannah Hunter,Isabelle Azais,Richard Eek,Heinz Gisslinger,Margaret Macro,Shaker Dakhil,Cristina Goncalves,Richard Leblanc,Ken Romeril,Bruno Royer,Chantal Doyen,Xavier Leleu,Fritz Offner,Nicolas Leupin,Vanessa Houck,Guang Chen,Annette Ervin-Haynes,Meletios A. Dimopoulos,Thierry Facon +28 more
TL;DR: Results support Rd continuous treatment as a new standard of care for stem-cell transplantation-ineligible patients with newly diagnosed multiple myeloma of all ages.
Journal ArticleDOI
Initial Phase 3 Results Of The First (Frontline Investigation Of Lenalidomide + Dexamethasone Versus Standard Thalidomide) Trial (MM-020/IFM 07 01) In Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Ineligible For Stem Cell Transplantation (SCT)
Thierry Facon,Meletios A. Dimopoulos,Angela Dispenzieri,John Catalano,Andrew Belch,Cyrille Hulin,Michele Cavo,Antonella Pinto,Katja Weisel,Heinz Ludwig,Nizar J. Bahlis,Anne Banos,Mourad Tiab,Michel Delforge,James D. Cavenagh,Catarina Geraldes,Je-Jung Lee,Christine Chen,Albert Oriol,Javier de la Rubia,Lugui Qiu,Darrell White,Daniel Binder,Kenneth C. Anderson,Philippe Moreau,Michel Attal,Robert Knight,Guang Chen,Jason Van Oostendorp,Christian Jacques,Annette Ervin-Haynes,Lofti Benboubker +31 more
TL;DR: Continuous treatment with the all oral doublet Rd significantly improved the primary endpoint of PFS compared with the standard triplet, MPT, and all secondary endpoints support the clinical benefit of continuous Rd treatment.
Journal ArticleDOI
Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma
Meletios A. Dimopoulos,Matthew C. Cheung,Murielle Roussel,Ting Liu,Barbara Gamberi,Brigitte Kolb,H. Guenter Derigs,Hyeon Seok Eom,Karim Belhadj,Pascal Lenain,Richard van der Jagt,Sophie Rigaudeau,Mamoun Dib,Rachel Hall,H. Jardel,Arnaud Jaccard,Axel Tosikyan,Lionel Karlin,William I. Bensinger,Rik Schots,Nicolas Leupin,Guang Chen,Jennifer Marek,Annette Ervin-Haynes,Thierry Facon +24 more
TL;DR: Overall survival benefits were observed with continuous lenalidomide and dexamethasone treatment vs. melphalan, prednisone, and thalidomides treatment in no or mild renal impairment subgroups, except for grade 3/4 anemia and rash, which increased with increasing severity of renal impairment.